Erythropoietin intraperitoneal

Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD. Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant erythropoietin in patients on CAPD. A rationale for treatment. Contrib Nephrol 1989 76 112-21. 

Kausz AT, Watkins SL, Hansen C, Godtvin DA, Palmer RB, Brandt JR. Intraperitoneal erythropoietin in children on peritoneal dialysis A study of pharmacokinetics and efficacy. Am J Kidney Dis 1999 34(4) 651-6. 

Ateshkadi A, et al. Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993 21 635-642. 

Many PD patients secrete large quantities of fibrinogen into the peritoneal cavity, which results in fibrin formation. This can lead to intraperitoneal adhesions and outflow obstruction. Intraperitoneal heparin may prevent this complication as a result of its local an-tiflbrin effect. Because standard heparin has a molecular weight of 12,000 to 15,000 daltons, it is minimally absorbed and thereby has limited systemic effects. The absorption of intraperitoneal erythropoietin has also been studied. Its bioavailability is low, but may be increased when added into a dry peritoneum. ... 

Boelaert J R, Schurgers M L, Matthys E G, et al. (1989). Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routs in continuous ambulatory peritoneal dialysis patients. Perit. Dial, hit. 9 95-98. 

Kampf D, Kahl A, Passlick J, et al. (1989). 8ingle-dose kinetics of recombinant hnman erythropoietin after intravenous, subcutaneous and intraperitoneal administration. Contrib. Nephrol. 76 106-111. 

Icardi A, Paoletti E, Molinelli G (1990). Efficacy of recombinant erythropoietin after subcutaneous or intraperitoneal administration to patients on CAPD. Adv. Peril. Dial. 6 292-295. 

Nasu T, Mitui H, 8hinohara Y, et al. (1992). Effect of erythropoietin in continuous ambulatory peritoneal dialysis patientscomparison between intravenous and intraperitoneal administration. Perit. Dial. Int. 12 373-377. 

Huang T P, Lin C Y (1995). Intraperitoneal recombinant human erythropoietin therapy Influence of the duration of continuous ambulatory peritoneal dialysis treatment and peritonitis. Am. J. Nephrol. 15 312-317. 

Bargman J M, Jones J E, Petro J M (1992). The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate. Perit. Dial. Int. 12 369-372. 

---